Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism

Read More

Ligand Reports Second Quarter 2016 Financial Results

Read More

Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals

Read More

Recent Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range